# Commonly Requested Compounding Ideas for Patients Needing Hormone Replacement Therapy (HRT)





# Noblesville Pharmacy

RX and Custom Compounding

758 Westfield Rd. Noblesville, IN 46062

Phone: 317-231-5252

Fax: 317-900-7458

#### **Progesterone**

For more information, see PCCA Document #97711, VersaBase Cream, Gel, Cosmetic HRT/Progesterone Study Results.

| PCCA Formula # 12114 | Progesterone 10 mg/Gm to 100 mg/Gm Topical Cream             |
|----------------------|--|
|                      | (VersaBase®) (FormulaPlus™ BUD Bracketed Study)              |
| PCCA Formula # 10797 | Progesterone 100 mg Slow Release Capsules Size #1 (LoxOral®) |
| PCCA Formula # 3731  | Progesterone 100 mg/mL Oil Sublingual Suspension             |
| PCCA Formula # 12424 | Progesterone 200 mg Rapid Dissolve Tablet (RDT-Plus™)        |
| PCCA Formula # 12389 | Progesterone 100 mg Rapid Dissolve Tablet (RDT-Plus™)        |
| PCCA Formula # 12388 | Progesterone 75 mg Rapid Dissolve Tablet (RDT-Plus™)         |
| PCCA Formula # 12387 | Progesterone 50 mg Rapid Dissolve Tablet (RDT-Plus™)         |
| PCCA Formula # 12386 | Progesterone 25 mg Rapid Dissolve Tablet (RDT-Plus™)         |

#### **Estriol/Estradiol**

| PCCA Formula # 12017 | Estriol/Estradiol [50%/50%] 0.5 mg/0.5 Gm Topical Cream      |
|----------------------|--|
|                      | (VersaBase®) (PCCA Dilution)                                 |
| PCCA Formula # 10241 | Estriol/Estradiol [80%/20%] 5 mg/mL Topical Gel (VersaBase®) |
| PCCA Formula # 10885 | Estriol/Estradiol [30%/70%] 1 mg/0.5 Gm Topical Cream        |
| PCCA Formula # 12116 | Estriol/Estradiol [50%/50%] 0.25 mg/0.5 Gm to 1 mg/0.5 Gm    |
|                      | Topical Cream (VersaBase®) (FormulaPlus BUD Bracketed Study) |

# **Estriol/Estradiol/Progesterone**

| Estriol/Estradiol/Progest | erone  |
|---------------------------|--|
| PCCA Formula # 12115      | Estriol/Estradiol [50%/50%] 0.25 mg/0.5 Gm to 1 mg/0.5 Gm/<br>Progesterone 5 mg/0.5 Gm to 50 mg/0.5 Gm Topical Cream<br>(VersaBase®) (FormulaPlus BUD Bracketed Study) |
| PCCA Formula # 11304      | Estriol/Estradiol [80%/20%] 0.1 mg/0.1 mL/Progesterone 10 mg/0.1 mL Topical Cream (VersaBase®)   |
| PCCA Formula # 11296      | Estriol/Estradiol [80%/20%] 2 mg/Progesterone 100 mg/<br>Testosterone 0.5 mg/DHEA 25 mg Slow Release Capsules Size #0<br>(LoxOral™)                                    |
| PCCA Formula # 11297      | Estriol/Estradiol [80%/20%] 2 mg/Progesterone 100 mg Slow<br>Release Capsules Size #1 (LoxOral™)   |

#### **Testosterone**

| PCCA Formula # 11641 | Testosterone 1% Topical Cream (VersaBase®)               |
|----------------------|--|
|                      | (FormulaPlus BUD Study)                                  |
| PCCA Formula # 12099 | Estriol/Estradiol [80%/20%] 1 mg/Gm/Testosterone 1 mg/Gm |
|                      | Topical Cream (VersaBase®) (PCCA Dilution)               |
| PCCA Formula # 12391 | Testosterone 0.5 mg Rapid Dissolve Tablet (RDT-Plus™)    |
| PCCA Formula # 12392 | Testosterone 5 mg Rapid Dissolve Tablet (RDT-Plus™)      |
|                      |  |

# **DHEA**

| PCCA Formula # 12390 | Dehydroepiandrosterone 25 mg Rapid Dissolve Tablet |
|----------------------|--|
|                      | (RDT-Plus™)  |

# See the below Commonly Requested Compounding Idea Sheets for more information:

- For Patients Experiencing Female Sexual Dysfunction & Low Libido, see PCCA Document #97920 on the Members-Only Website.
- For Women's Health, see PCCA Document #98287.

# Learn more about these PCCA products:

- PCCA Special Micronized
   Progesterone USP (PCCA #30-3530) Not all hormone powders
   are alike. Particle size is very
   important in drug delivery,
   regardless if it is transdermal, oral,
   buccal, vaginal or rectal, and our
   Special Micronized Progesterone is
   99% less than 5 microns. Check out
   PCCA Document #97624 for more
   information.
- PCCA Estriol and Estradiol Dilutions (PCCA #55-4893 and #55-4892) -PCCA is the only company in the compounding industry that offers 10 mg/Gm dilutions of both micronized estriol (E3) and micronized estradiol (E2) in solution to meet the specialized needs of compounding pharmacists. Each 1 Gm of PCCA Estriol Dilution contains 0.01 Gm (10 mg) of estriol, and each 1 Gm of PCCA Estradiol Dilution contains 0.01 Gm (10 mg) of estradiol in a 100% naturally derived, patentpending solvent system.



# Commonly Requested Compounding Ideas for Patients Needing Hormone Replacement Therapy (HRT) (cont'd)

#### Commonly Requested Formulations for Patients with Vaginal Dryness or Atrophy

For more information, see PCCA Document #98289, Treatment Options for Vaginal Atrophy: What do the New Studies Show? by Annie DeReese; PCCA Document #99204, Women's Health and What You Need to Know by Sara Hover; and PCCA Document #99227, Estrogen Vaginal Preparations by Andrea Branvold-Herr.

### **Estriol**

| ESTRIOI              |   |
|----------------------|---|
| PCCA Formula # 11115 | Estriol 0.05% Vaginal Gel (MucoLox™/VersaBase®)                                     |
| PCCA Formula # 12229 | Estriol 0.025% to 1% Vaginal Cream (VersaBase®) (FormulaPlus BUD Bracketed Study)   |
| PCCA Formula # 12033 | Estriol 0.05% Vaginal Gel (MucoLox™/VersaBase®)<br>(PCCA Dilution)                  |
| PCCA Formula # 12032 | Estriol 0.1%/Testosterone 0.1% Vaginal Gel<br>(MucoLox™/VersaBase®) (PCCA Dilution) |
| PCCA Formula # 10568 | Estriol 1 mg/0.25 mL/Testosterone 1 mg/0.25 mL Vaginal Cream                        |
| Estradiol            |   |
| PCCA Formula # 12111 | Estradiol 10 mcg Vaginal Suppository (Tablet Triturate 200 mg Mold)                 |
| PCCA Formula # 11958 | Acidophilus 135 MU/Gm/Estradiol 0.01% Vaginal Gel                                   |

# **Estriol/Estradiol**

PCCA Formula # 12031 Estriol/Estradiol [50%/50%] 0.5 mg/0.5 Gm Vaginal Gel (MucoLox™/VersaBase®) (PCCA Dilution)

(MucoLox<sup>™</sup>/VersaBase<sup>®</sup>)

#### Other

PCCA Formula # 11118 Hyaluronic Acid 5 mg/Gm Compound Vaginal Gel (MucoLox™/VersaBase®) Non-hormonal option for

patients with vaginal dryness.

# **Commonly Requested Formulas for Patients with Vulvodynia**

| PCCA Formula # 11108 | Amitriptyline HCl 2%/Baclofen 2% Vaginal Gel (MucoLox™) |
|----------------------|---|
| PCCA Formula # 11110 | Gabapentin 6% Vaginal Gel (MucoLox™/VersaBase®)         |

#### **Commonly Requested Formulations for Patients with Female Sexual Dysfunction**

| PCCA Formula # 11949 | Aminophylline 3%/Arginine HCl 6% Topical Gel (MucoLox™) |
|----------------------|---|
| PCCA Formula # 11948 | Sildenafil 1%/Testosterone 0.1% Topical Gel (MucoLox™)  |
| PCCA Formula # 11947 | Testosterone 0.2% Vaginal Gel (MucoLox™/VersaBase®)     |

#### Learn more about these PCCA bases:

- MucoLox™ (PCCA #30-4782) is a revolutionary mucosal delivery system that provides long-lasting coverage and improves contact time. This innovative base can be used with active pharmaceutical ingredients (APIs) in a variety of potential formulations, including oral, rectal, vaginal and esophageal/gut preparations as well as wound care. MucoLox can be thickened for use as a vaginal gel by mixing equal parts MucoLox and VersaBase Gel or by adding a gelling agent such as carboxymethylcellulose (see PCCA Formula #11189 -Carboxymethylcellulose Sodium 1.75% Gel (MucoLox™)).
- LoxOral™ (PCCA #30-4774) is the only excipient capsule base that can be used in any type of oral capsule formulation, and with any type of active ingredient. So much more than a filler - LoxOral is an innovative capsule excipient base that delivers powerful benefits: improved dissolution; even distribution; optimal stability; and ease of use.

The formulas and/or statements listed are provided for educational purposes only. They are compounding ideas that have commonly been requested by physicians, and have not been evaluated by the Food and Drug Administration. Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.

